Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the overall dyslipidemia drug-treated population will increase by 4% annually. Primary factors driving the rise in drug treatment in this population include increasing awareness of its coronary heart disease risk coupled with the availability of low-cost, generic statin substitutes to treat these patients.

The new Pharmacor study entitled Dyslipidemia also finds that Pfizer and Merck plan to fight back against generic erosion of atorvastatin and simvastatin, two leading statins.

"The launch of Pfizer's atorvastatin/torcetrapib and atorvastatin/amlodipine, and of Merck/Schering-Plough's simvastatin/ezetimibe will provide effective defense strategies for these two leading statins against significant generic erosion," said Nicola Maidwell, Ph.D., analyst at Decision Resources. "These combination therapies address key unmet needs such as treatment of secondary therapeutic goals, including triglycerides (TGs) and high-density lipoprotein (HDL)."

About Dyslipidemia

Dyslipidemia describes any abnormality in serum lipid concentration, be it above or below desired levels. Serum concentrations of low-density lipoprotein (LDL), and TGs may be raised, or HDL may be decreased. The market for lipid- lowering therapies is one of the most lucrative in the pharmaceutical arena.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Dermatology Drug Market Will Experience Modest Growth of 8% Per Year Through 2008

View Now